Psychedelic law reform under local law began recently when Denver voters decriminalized psilocybin mushrooms. The reform movement has spread quickly across the United States, generating both headlines and conflict between pharmaceutical companies seeking FDA-approval of psychedelic drugs and activists opposed to commercialization.

Oregon voters legalized psilocybin-assisted therapy in clinics using products manufactured under state licenses. What patent protections are available to licensees in a state "medical psychedelic" program? Can pharmaceutical companies with FDA-approved psychedelic medicine restrict the operations of state-licensed actors and the legacy market?